What is the role of trabectedin (Yondelis) in the treatment of liposarcoma?

Updated: Mar 18, 2020
  • Author: Robert A Schwartz, MD, MPH; Chief Editor: Dirk M Elston, MD  more...
  • Print

Trabectedin (Yondelis) was approved in November 2015 in the United States for unresectable or metastatic liposarcoma or leiomyosarcoma in patients who have received a prior anthracycline-containing regimen. It is an alkylating drug that binds guanine residues in the minor groove of DNA. Approval was based on a phase 3 trial (n=518) that showed a statistically significant improvement in progression-free survival compared with dacarbazine (4.2 mo vs 1.5 mo; P<.0001). No improvement in overall survival was observed. [38]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!